Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...
China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals
The National Medical Products Administration (NMPA) of China has given the green light to Beijing...
China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System
In a bid to address the evolving healthcare needs of an aging population and a...
AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal
US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...
Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico
Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...
Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...
Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...
Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...
Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...
ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...
Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...
AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...
Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...
Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia
China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...
Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus
Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...
US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry
Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...
China’s Health Authorities Set Standards for Key Central Township Health Centers
The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...
China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”
The State Council of China has released a “Five Year Action Plan for Deepening the...